Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves’ disease
Authors:
- Bartłomiej KisielBKBartłomiej Kisiel
- Tomasz BednarczukTBTomasz Bednarczuk
- Grazyna KostrzewaGKGrazyna Kostrzewa
- Joanna KosińskaJKJoanna Kosińska
- Piotr MiśkiewiczPMPiotr Miśkiewicz
- Maria Teresa PłazińskaMPMaria Teresa Płazińska
- Ewa Bar-AndziakEBEwa Bar-Andziak
- Leszek KrólickiLKLeszek Królicki
- Paweł KrajewskiPKPaweł Krajewski
- Rafał PłoskiRPRafał Płoski
- 10 September 2007
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 68 (3) , 429-434
Abstract
Objective To investigate whether a polymorphism in the ESR2 gene (rs4986938, previously associated with endometriosis, ovulatory dysfunction and premature onset of coronary heart disease) increases the risk of Graves’ disease (GD). Subjects and design A cohort of 375 GD patients (300 females and 75 males) and 1001 individuals representative of the background population of Poland (502 males and 499 females) were genotyped for rs4986938 using allele‐specific polymerase chain reaction (PCR). Results We found an increased frequency of the ESR2 A allele among the patients vs. controls (38·0%vs. 32·7%, OR = 1·26, P = 0·009) that was caused by a co‐dominant (OR = 1·25, P = 0·01, Pfor model fit = 0·127) or a recessive (OR = 1·67, P = 0·003, Pfor model fit = 0·554) effect. The association was found in both sexes (OR = 1·21, P = 0·046 and OR = 1·53, P = 0·029, respectively, for co‐dominant and recessive models in females, and OR = 1·44, P = 0·034 and OR = 2·29, P = 0·01, respectively, for the two models in males) and was more pronounced among the DRB1*03‐negative (OR = 1·63, P = 0·0002) than DRB1*03‐positive patients (OR = 1·04, P = 0·822). No other statistically significant associations between the ESR2 genotype and GD subsets were found (age of onset, smoking, clinically evident ophthalmopathy, family history of GD, and PTPN22 and CTLA4 (CT60) genotypes were analysed). Conclusions In a Polish population the ESR2 A allele is associated with GD with a strength comparable to polymorphisms of PTPN22 and CTLA4 CT60 loci (OR ~ 1·7). The association with ESR2 is found in both sexes and may be particularly strong among the DRB1*03‐negative individuals.Keywords
This publication has 28 references indexed in Scilit:
- The Codon 620 Tryptophan Allele of the Lymphoid Tyrosine Phosphatase (LYP) Gene Is a Major Determinant of Graves’ DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2004
- Replication of an Association Between the Lymphoid Tyrosine Phosphatase Locus (LYP/PTPN22) With Type 1 Diabetes, and Evidence for Its Role as a General Autoimmunity LocusDiabetes, 2004
- Polymorphisms in the estrogen receptor β gene but not estrogen receptor α gene affect the risk of developing endometriosis in a Japanese populationFertility and Sterility, 2004
- Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyondClinical and Experimental Immunology, 2004
- Common and Unique Susceptibility Loci in Graves and Hashimoto Diseases: Results of Whole-Genome Screening in a Data Set of 102 Multiplex FamiliesThe American Journal of Human Genetics, 2003
- Lack of association between estrogen receptor β dinucleotide repeat polymorphism and autoimmune thyroid diseases in Japanese patientsBMC Medical Genetics, 2001
- The genetic susceptibility to Graves' diseaseBailliere's Clinical Endocrinology and Metabolism, 1997
- Mapping of a Major Susceptibility Locus for Graves' Disease (GD-1) to Chromosome 14q31The Journal of Clinical Endocrinology & Metabolism, 1997
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- Localization of the human oestrogen receptor gene to chromosome 6q24→q27 by in situ hybridizationCytogenetic and Genome Research, 1986